{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T18:10:23Z","timestamp":1758823823724},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,10,14]],"date-time":"2009-10-14T00:00:00Z","timestamp":1255478400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s11912-009-0063-x","type":"journal-article","created":{"date-parts":[[2009,10,13]],"date-time":"2009-10-13T02:35:00Z","timestamp":1255401300000},"page":"466-472","source":"Crossref","is-referenced-by-count":11,"title":["Novel imaging modalities in gynecologic cancer"],"prefix":"10.1007","volume":"11","author":[{"given":"Rebecca A.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,14]]},"reference":[{"key":"63_CR1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A. Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225\u2013249.","journal-title":"CA Cancer J Clin"},{"key":"63_CR2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra050276","volume":"354","author":"M.E. Juweid","year":"2006","unstructured":"Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006, 354:496\u2013507.","journal-title":"N Engl J Med"},{"key":"63_CR3","first-page":"266","volume":"45","author":"H. Lerman","year":"2004","unstructured":"Lerman H, Metser U, Grisaru D, et al.: Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET\/CT. J Nucl Med 2004, 45:266\u2013271.","journal-title":"J Nucl Med"},{"key":"63_CR4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00259-004-1703-x","volume":"32","author":"S. Nishizawa","year":"2005","unstructured":"Nishizawa S, Inubushi M, Okada H: Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging 2005, 32:549\u2013556.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00259-005-1771-6","volume":"32","author":"S.K. Kim","year":"2005","unstructured":"Kim SK, Kang KW, Roh JW, et al.: Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. Eur J Nucl Med Mol Imaging 2005, 32:757\u2013763.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ygyno.2005.06.019","volume":"99","author":"R.E. Bristow","year":"2005","unstructured":"Bristow RE, Giuntoli RL 2nd, Pannu HK, et al.: Combined PET\/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 2005, 99:294\u2013300.","journal-title":"Gynecol Oncol"},{"key":"63_CR7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00259-006-0251-y","volume":"34","author":"S. Sironi","year":"2007","unstructured":"Sironi S, Picchio M, Landoni C, et al.: Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET\/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007, 34:472\u2013479.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0090-8258(03)00336-6","volume":"90","author":"R.E. Bristow","year":"2003","unstructured":"Bristow RE, del Carmen MG, Pannu HK, et al.: Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET\/CT. Gynecol Oncol 2003, 90:519\u2013528.","journal-title":"Gynecol Oncol"},{"key":"63_CR9","first-page":"1051","volume":"44","author":"T. Torizuka","year":"2003","unstructured":"Torizuka T, Kanno T, Futatsubashi M, et al.: Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003, 44:1051\u20131056.","journal-title":"J Nucl Med"},{"key":"63_CR10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2214\/ajr.176.6.1761449","volume":"176","author":"Y. Nakamoto","year":"2001","unstructured":"Nakamoto Y, Saga T, Ishimori T, et al.: Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol 2001, 176:1449\u20131454.","journal-title":"AJR Am J Roentgenol"},{"key":"63_CR11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/gyno.2001.6386","volume":"83","author":"M. Zimny","year":"2001","unstructured":"Zimny M, Siggelkow W, Schroder W, et al.: 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001, 83:310\u2013315.","journal-title":"Gynecol Oncol"},{"key":"63_CR12","first-page":"3691","volume":"21","author":"R.F. Yen","year":"2001","unstructured":"Yen RF, Sun SS, Shen YY, et al.: Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001, 21:3691\u20133694.","journal-title":"Anticancer Res"},{"key":"63_CR13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","volume":"103","author":"B. Simcock","year":"2006","unstructured":"Simcock B, Neesham D, Quinn M, et al.: The impact of PET\/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006, 103:271\u2013276.","journal-title":"Gynecol Oncol"},{"key":"63_CR14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2007.07.082","volume":"108","author":"M. Soussan","year":"2008","unstructured":"Soussan M, Wartski M, Cherel P, et al.: Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 2008, 108:160\u2013165.","journal-title":"Gynecol Oncol"},{"key":"63_CR15","first-page":"2303","volume":"28","author":"M.S. Lenhard","year":"2008","unstructured":"Lenhard MS, Burges A, Johnson TR, et al.: PET-CT in recurrent ovarian cancer: impact on treatment planning. Anticancer Res 2008, 28:2303\u20132308.","journal-title":"Anticancer Res"},{"key":"63_CR16","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","volume":"23","author":"N. Avril","year":"2005","unstructured":"Avril N, Sassen S, Schmalfeldt B, et al.: Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005, 23:7445\u20137453.","journal-title":"J Clin Oncol"},{"key":"63_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-6-1","volume":"6","author":"S.P. Povoski","year":"2008","unstructured":"Povoski SP, Hall NC, Martin EW Jr, Walker MJ: Multimodality approach of perioperative 18F-FDG PET\/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma. World J Surg Oncol 2008, 6:1.","journal-title":"World J Surg Oncol"},{"key":"63_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1477-7819-5-143","volume":"5","author":"N.C. Hall","year":"2007","unstructured":"Hall NC, Povoski SP, Murrey DA, et al.: Combined approach of perioperative 18F-FDG PET\/CT imaging and intraoperative 18F-FDG handheld gamma probe detection for tumor localization and verification of complete tumor resection in breast cancer. World J Surg Oncol 2007, 5:143.","journal-title":"World J Surg Oncol"},{"key":"63_CR19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2008.04.026","volume":"110","author":"D.E. Cohn","year":"2008","unstructured":"Cohn DE, Hall NC, Povoski SP, et al.: Novel perioperative imaging with 18F-FDG PET\/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer. Gynecol Oncol 2008, 110:152\u2013157.","journal-title":"Gynecol Oncol"},{"key":"63_CR20","first-page":"2196","volume":"36","author":"M. Lapela","year":"1995","unstructured":"Lapela M, Leskinen-Kallio S, Varpula M, et al.: Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med 1995, 36:2196\u20132200.","journal-title":"J Nucl Med"},{"key":"63_CR21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MNM.0b013e328313b7bc","volume":"30","author":"P. Lindholm","year":"2009","unstructured":"Lindholm P, Lapela M, Nagren K, et al.: Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 2009, 30:30\u201336.","journal-title":"Nucl Med Commun"},{"key":"63_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3233\/CBM-2009-0543","volume":"5","author":"P. Narayanan","year":"2009","unstructured":"Narayanan P, Iyngkaran T, Sohaib SA, et al.: Magnetic resonance lymphography: a novel technique for lymph node assessment in gynecologic malignancies. Cancer Biomark 2009, 5:81\u201388.","journal-title":"Cancer Biomark"},{"key":"63_CR23","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/cncr.21527","volume":"104","author":"J.D. Wright","year":"2005","unstructured":"Wright JD, Dehdashti F, Herzog TJ, et al.: Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005, 104:2484\u20132491.","journal-title":"Cancer"},{"key":"63_CR24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2007.03.027","volume":"106","author":"A. Loft","year":"2007","unstructured":"Loft A, Berthelsen AK, Roed H, et al.: The diagnostic value of PET\/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007, 106:29\u201334.","journal-title":"Gynecol Oncol"},{"key":"63_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1200\/JCO.1999.17.1.41","volume":"17","author":"P.G. Rose","year":"1999","unstructured":"Rose PG, Adler LP, Rodriguez M, et al.: Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999, 17:41\u201345.","journal-title":"J Clin Oncol"},{"key":"63_CR26","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2001.19.17.3745","volume":"19","author":"P.W. Grigsby","year":"2001","unstructured":"Grigsby PW, Siegel BA, Dehdashti F: Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001, 19:3745\u20133749.","journal-title":"J Clin Oncol"},{"key":"63_CR27","first-page":"1125","volume":"40","author":"Y. Sugawara","year":"1999","unstructured":"Sugawara Y, Eisbruch A, Kosuda S, et al.: Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999, 40:1125\u20131131.","journal-title":"J Nucl Med"},{"key":"63_CR28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2006.09.009","volume":"104","author":"H.H. Chung","year":"2007","unstructured":"Chung HH, Jo H, Kang WJ, et al.: Clinical impact of integrated PET\/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007, 104:529\u2013534.","journal-title":"Gynecol Oncol"},{"key":"63_CR29","first-page":"1632","volume":"45","author":"T.C. Yen","year":"2004","unstructured":"Yen TC, See LC, Chang TC, et al.: Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004, 45:1632\u20131639.","journal-title":"J Nucl Med"},{"key":"63_CR30","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.2004.09.035","volume":"22","author":"P.W. Grigsby","year":"2004","unstructured":"Grigsby PW, Siegel BA, Dehdashti F, et al.: Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004, 22:2167\u20132171.","journal-title":"J Clin Oncol"},{"key":"63_CR31","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1001\/jama.298.19.2289","volume":"298","author":"J.K. Schwarz","year":"2007","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW: Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007, 298:2289\u20132295.","journal-title":"JAMA"},{"key":"63_CR32","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.ygyno.2007.07.034","volume":"107","author":"P.W. Grigsby","year":"2007","unstructured":"Grigsby PW: The role of FDG-PET\/CT imaging after radiation therapy. Gynecol Oncol 2007, 107:S27\u2013S29.","journal-title":"Gynecol Oncol"},{"key":"63_CR33","first-page":"347","volume":"44","author":"S.Y. Ryu","year":"2003","unstructured":"Ryu SY, Kim MH, Choi SC, et al.: Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003, 44:347\u2013352.","journal-title":"J Nucl Med"},{"key":"63_CR34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0090-8258(03)00256-7","volume":"90","author":"L.J. Havrilesky","year":"2003","unstructured":"Havrilesky LJ, Wong TZ, Secord AA, et al.: The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003, 90:186\u2013190.","journal-title":"Gynecol Oncol"},{"key":"63_CR35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2004.04.021","volume":"94","author":"J.B. Unger","year":"2004","unstructured":"Unger JB, Ivy JJ, Connor P, et al.: Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol 2004, 94:212\u2013216.","journal-title":"Gynecol Oncol"},{"key":"63_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/gyno.2000.5860","volume":"78","author":"D. Bodurka-Bevers","year":"2000","unstructured":"Bodurka-Bevers D, Morris M, Eifel PJ, et al.: Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol 2000, 78:187\u2013193.","journal-title":"Gynecol Oncol"},{"key":"63_CR37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2006.02.016","volume":"103","author":"H.H. Chung","year":"2006","unstructured":"Chung HH, Kim SK, Kim TH, et al.: Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis. Gynecol Oncol 2006, 103:165\u2013170.","journal-title":"Gynecol Oncol"},{"key":"63_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2008.08.028","volume":"112","author":"R.A. Brooks","year":"2009","unstructured":"Brooks RA, Rader JS, Dehdashti F, et al.: Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009, 112:104\u2013109.","journal-title":"Gynecol Oncol"},{"key":"63_CR39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncr.20349","volume":"101","author":"T.C. Chang","year":"2004","unstructured":"Chang TC, Law KS, Hong JH, et al.: Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 2004, 101:164\u2013171.","journal-title":"Cancer"},{"key":"63_CR40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00006231-200606000-00002","volume":"27","author":"T. Torizuka","year":"2006","unstructured":"Torizuka T, Nakamura F, Takekuma M, et al.: FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer. Nucl Med Commun 2006, 27:481\u2013487.","journal-title":"Nucl Med Commun"},{"key":"63_CR41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ygyno.2007.11.044","volume":"108","author":"J.Y. Park","year":"2008","unstructured":"Park JY, Kim EN, Kim DY, et al.: Comparison of the validity of magnetic resonance imaging and positron emission tomography\/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008, 108:486\u2013492.","journal-title":"Gynecol Oncol"},{"key":"63_CR42","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ygyno.2004.08.009","volume":"95","author":"N.S. Horowitz","year":"2004","unstructured":"Horowitz NS, Dehdashti F, Herzog TJ, et al.: Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004, 95:546\u2013551.","journal-title":"Gynecol Oncol"},{"key":"63_CR43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02990022","volume":"17","author":"T. Saga","year":"2003","unstructured":"Saga T, Higashi T, Ishimori T, et al.: Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003, 17:197\u2013203.","journal-title":"Ann Nucl Med"},{"key":"63_CR44","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00259-007-0687-8","volume":"35","author":"H.H. Chung","year":"2008","unstructured":"Chung HH, Kang WJ, Kim JW, et al.: The clinical impact of [(18)F]FDG PET\/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. Eur J Nucl Med Mol Imaging 2008, 35:1081\u20131088.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR45","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2008.01.030","volume":"109","author":"J.Y. Park","year":"2008","unstructured":"Park JY, Kim EN, Kim DY, et al.: Role of PET or PET\/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol 2008, 109:255\u2013262.","journal-title":"Gynecol Oncol"},{"key":"63_CR46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00259-007-0533-z","volume":"35","author":"K.C. Ho","year":"2008","unstructured":"Ho KC, Lai CH, Wu TI, et al.: 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging 2008, 35:484\u2013492.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR47","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0b013e3180a1ac9d","volume":"32","author":"J. Bachmann","year":"2007","unstructured":"Bachmann J, Ernestus K, Werner T, et al.: Detection of primary choriocarcinoma in the mediastinum by F-18 FDG positron emission tomography. Clin Nucl Med 2007, 32:663\u2013665.","journal-title":"Clin Nucl Med"},{"key":"63_CR48","first-page":"897","volume":"51","author":"R. Cortes-Charry","year":"2006","unstructured":"Cortes-Charry R, Figueira LM, Nieves L, Colmenter L: Metastasis detection with 18 FDG-positron emission tomography\/computed tomography in gestational trophoblastic neoplasia: a report of 2 cases. J Reprod Med 2006, 51:897\u2013901.","journal-title":"J Reprod Med"},{"key":"63_CR49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ygyno.2005.01.049","volume":"97","author":"T.M. Numnum","year":"2005","unstructured":"Numnum TM, Leath CA 3rd, Straughn JM Jr, et al.: Occult choriocarcinoma discovered by positron emission tomo graphy\/computed tomography imaging following a successful pregnancy. Gynecol Oncol 2005, 97:713\u2013715.","journal-title":"Gynecol Oncol"},{"key":"63_CR50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ijrobp.2004.12.011","volume":"62","author":"W.T. Lamoreaux","year":"2005","unstructured":"Lamoreaux WT, Grigsby PW, Dehdashti F, et al.: FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005, 62:733\u2013737.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"63_CR51","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s11095-007-9250-3","volume":"24","author":"R.M. Stephen","year":"2007","unstructured":"Stephen RM, Gillies RJ: Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007, 24:1172\u20131185.","journal-title":"Pharm Res"},{"key":"63_CR52","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ijrobp.2005.08.014","volume":"63","author":"A.R. Gottschalk","year":"2005","unstructured":"Gottschalk AR, Doan A, Nakamura JL, et al.: Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int J Radiat Oncol Biol Phys 2005, 63:1221\u20131227.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"63_CR53","doi-asserted-by":"crossref","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","volume":"11","author":"L. Hu","year":"2005","unstructured":"Hu L, Hofmann J, Holash J, et al.: Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966\u20136971.","journal-title":"Clin Cancer Res"},{"key":"63_CR54","doi-asserted-by":"crossref","first-page":"770s","DOI":"10.1158\/1078-0432.CCR-06-1921","volume":"13","author":"M.A. Rosen","year":"2007","unstructured":"Rosen MA, Schnall MD: Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 2007, 13:770s\u2013776s.","journal-title":"Clin Cancer Res"},{"key":"63_CR55","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.urolonc.2004.01.011","volume":"22","author":"R.R. Jennens","year":"2004","unstructured":"Jennens RR, Rosenthal MA, Lindeman GJ, Michael M: Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. Urol Oncol 2004, 22:193\u2013196.","journal-title":"Urol Oncol"},{"key":"63_CR56","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00259-009-1111-3","volume":"36","author":"E. Samen","year":"2009","unstructured":"Samen E, Thorell JO, Lu L, et al.: Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2. Eur J Nucl Med Mol Imaging 2009, 36:1283\u20131295.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR57","first-page":"1127","volume":"47","author":"B.M. Tijink","year":"2006","unstructured":"Tijink BM, Neri D, Leemans CR, et al.: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 2006, 47:1127\u20131135.","journal-title":"J Nucl Med"},{"key":"63_CR58","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00259-003-1187-0","volume":"30","author":"D.L. Francis","year":"2003","unstructured":"Francis DL, Visvikis D, Costa DC, et al.: Potential impact of [18F]3\u2019-deoxy-3\u2019-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003, 30:988\u2013994.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"63_CR59","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/RCT.0b013e3180980db9","volume":"32","author":"Y. Yamamoto","year":"2008","unstructured":"Yamamoto Y, Nishiyama Y, Ishikawa S, et al.: 3\u2019-Deoxy-3\u2019-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18ffluoro-D-glucose. J Comput Assist Tomogr 2008, 32:432\u2013437.","journal-title":"J Comput Assist Tomogr"},{"key":"63_CR60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1378\/chest.129.2.393","volume":"129","author":"C.S. Yap","year":"2006","unstructured":"Yap CS, Czernin J, Fishbein MC, et al.: Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006, 129:393\u2013401.","journal-title":"Chest"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0063-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-009-0063-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0063-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:31:36Z","timestamp":1559421096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-009-0063-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,14]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s11912-009-0063-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,14]]}}}